Now available in New Brunswick, (Pr)ONBREZ* BREEZHALER*, a once-daily bronchodilator for chronic obstructive pulmonary disease (COPD)

ONBREZ* BREEZHALER* is a 24-hour long-acting β2-agonist (LABA) approved for maintenance treatment of airflow obstruction in patients with COPD.

DORVAL, QC, July 11, 2013 /CNW/ - New Brunswick patients suffering from chronic obstructive pulmonary disease (COPD) now have access to ONBREZ* BREEZHALER* (indacaterol maleate) 75 mcg with its listing in the New Brunswick Prescription Drug Program (NBPDP) formulary. ONBREZ* BREEZHALER* is available in pharmacies province wide.

ONBREZ* BREEZHALER* is a long-acting β2-agonist (LABA) indicated for long-term maintenance bronchodilator treatment of airflow obstruction in patients with COPD, including chronic bronchitis and emphysema. As an inhaled, steroid-free COPD treatment, ONBREZ* BREEZHALER* is not indicated for the relief of acute deterioration of COPD, nor to treat asthma1.

"We are pleased that New Brunswick recognized the therapeutic value of ONBREZ* BREEZHALER*, leading to its inclusion on the list of recommended drugs reimbursed by the New Brunswick Prescription Drug Program. Other provinces are also providing access to this new treatment for Canadians with COPD," said Dr. Riad Sherif B., President of Novartis Pharmaceuticals Canada Inc.

"This approval is welcome news for patients in New Brunswick, offering them a new option for COPD therapy." added Barbara MacKinnon President and CEO of the New Brunswick Lung Association.

About COPD
COPD is a chronic, progressive respiratory condition characterized by gradual airway obstruction, shortness of breath, cough and sputum production. 2009-2010 estimates show that 4% of Canadians are affected. Cigarette smoking is the principal cause, accounting for 80% of COPD deaths.2

About Novartis Pharmaceuticals Canada Inc.
Novartis Pharmaceuticals Canada Inc., a leader in the healthcare field, is committed to the discovery, development and marketing of innovative products to improve the well-being of all Canadians. In 2012, the company invested close to $100 million in research and development in Canada. Novartis Pharmaceuticals Canada Inc. employs more than 600 people in Canada. For further information, please consult www.novartis.ca.

*ONBREZ and BREEZHALER are registered trademarks.

References

1     ONBREZ* BREEZHALER* Product Monograph, October 24, 2012.
2     PHAC. Fast facts about Chronic Obstructive Pulmonary Disease (COPD) 2011. Available from: www.phac-aspc.gc.ca/cd-mc/publications/copd-mpoc/ff-rr-2011-eng.php. Accessed March 15, 2013.

SOURCE: Novartis Pharmaceuticals Canada Inc.

For further information:

Novartis - Media Relations

Andrea Gilpin
Director, Corporate Communications
Novartis Pharmaceuticals Canada Inc.
+1-514-633-7873
communications.camlph@novartis.com


FORFAITS PERSONNALISÉS

Jetez un coup d’œil sur nos forfaits personnalisés ou créez le vôtre selon vos besoins de communication particuliers.

Commencez dès aujourd'hui .

ADHÉSION À CNW

Remplissez un formulaire d'adhésion à CNW ou communiquez avec nous au 1-877-269-7890.

RENSEIGNEZ-VOUS SUR LES SERVICES DE CNW

Demandez plus d'informations sur les produits et services de CNW ou communiquez avec nous au 1‑877-269-7890.